News & Updates

Show Multimedia Only

Rescue combo therapy outshines albuterol alone for mild asthma

12 Nov 2025 by

As-needed treatment with the combination of albuterol plus budesonide works better than albuterol alone for preventing severe exacerbations in patients with uncontrolled mild asthma, according to the phase IIIb BATURA trial.

Rescue combo therapy outshines albuterol alone for mild asthma

12 Nov 2025

Short-course nafithromycin noninferior to 7-day moxifloxacin regimen for pneumonia

11 Nov 2025 by

A 3-day course of oral nafithromycin is equally efficacious as the 7-day course of oral moxifloxacin for the treatment of community-acquired bacterial pneumonia (CABP) in adults, as shown in a phase III study.

Short-course nafithromycin noninferior to 7-day moxifloxacin regimen for pneumonia

11 Nov 2025

Chemo-free treatment combination prolongs survival in previously treated mCRC

10 Nov 2025 by

Treatment with the multitargeted tyrosine-kinase inhibitor zanzalintinib, when combined with atezolizumab, confers an overall survival benefit in previously treated metastatic colorectal cancer (mCRC), according to the phase III STELLAR-303 trial.

Chemo-free treatment combination prolongs survival in previously treated mCRC

10 Nov 2025

Oral nitrates tied to lower risk of glaucoma in patients with chronic ischaemic heart disease

10 Nov 2025

In patients with chronic ischaemic heart disease (IHD), the use of oral nitrates helps lower the risk of open-angle glaucoma (OAG) and primary open-angle glaucoma (POAG), according to a retrospective study.

Oral nitrates tied to lower risk of glaucoma in patients with chronic ischaemic heart disease

10 Nov 2025

HER2-expressing urothelial cancer gets survival boost with disitamab vedotin–toripalimab combo

09 Nov 2025 by

In the frontline treatment of patients with HER2-expressing locally advanced or metastatic urothelial cancer, the combination of disitamab vedotin plus toripalimab yields a clinically meaningful and significant increase in survival compared with chemotherapy, as shown in the phase III RC48-C016 trial.

HER2-expressing urothelial cancer gets survival boost with disitamab vedotin–toripalimab combo

09 Nov 2025

Bexicaserin shows promise in developmental and epileptic encephalopathies

08 Nov 2025

In the treatment of patients with developmental and epileptic encephalopathies (DEEs), the selective serotonin 5-HT2C receptor agonist bexicaserin is well tolerated and appears to reduce the frequency of countable motor seizures, according to a phase Ib/IIa study.

Bexicaserin shows promise in developmental and epileptic encephalopathies

08 Nov 2025

Liraglutide promotes weight loss after suboptimal response to bariatric surgery

07 Nov 2025 by

For patients who are struggling to lose weight after metabolic bariatric surgery, treatment with liraglutide boosts weight-loss outcomes and helps avoid conversion surgery, as shown in a randomized clinical trial.

Liraglutide promotes weight loss after suboptimal response to bariatric surgery

07 Nov 2025

Bemarituzumab extends survival in FGFR2b-overexpressing gastric cancer

07 Nov 2025 by

The use of bemarituzumab in combination with chemotherapy provides statistically significant survival benefits among patients with advanced or metastatic FGFR2b-overexpressing gastric or gastroesophageal junction cancer (G/GEJC) in the primary analysis of the phase III FORTITUDE-101 trial.

Bemarituzumab extends survival in FGFR2b-overexpressing gastric cancer

07 Nov 2025

First-line sacituzumab govitecan ups PFS in metastatic TBNC

07 Nov 2025 by

First-line treatment with sacituzumab govitecan, an antibody drug conjugate, significantly improved progression-free survival (PFS) compared with chemotherapy in patients with metastatic triple-negative breast cancer (TNBC), according to the ASCENT-03 trial presented at ESMO 2025.

First-line sacituzumab govitecan ups PFS in metastatic TBNC

07 Nov 2025

Datopotamab deruxtecan improves survival in breast cancer patients not eligible for immunotherapy

06 Nov 2025 by

First-line treatment with datopotamab deruxtecan (Dato-DXd) results in statistically significant and clinically meaningful improvements in overall survival (OS) and progression-free survival (PFS) compared with chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC), as shown by the results of the phase III TROPION-Breast02 trial.

Datopotamab deruxtecan improves survival in breast cancer patients not eligible for immunotherapy

06 Nov 2025

News & Updates

Filter by Specialty:

Specialty:

Rescue combo therapy outshines albuterol alone for mild asthma

Rescue combo therapy outshines albuterol alone for mild asthma

Short-course nafithromycin noninferior to 7-day moxifloxacin regimen for pneumonia

Short-course nafithromycin noninferior to 7-day moxifloxacin regimen for pneumonia

Chemo-free treatment combination prolongs survival in previously treated mCRC

Chemo-free treatment combination prolongs survival in previously treated mCRC

Oral nitrates tied to lower risk of glaucoma in patients with chronic ischaemic heart disease

Oral nitrates tied to lower risk of glaucoma in patients with chronic ischaemic heart disease

HER2-expressing urothelial cancer gets survival boost with disitamab vedotin–toripalimab combo

HER2-expressing urothelial cancer gets survival boost with disitamab vedotin–toripalimab combo

Bexicaserin shows promise in developmental and epileptic encephalopathies

Bexicaserin shows promise in developmental and epileptic encephalopathies

Liraglutide promotes weight loss after suboptimal response to bariatric surgery

Liraglutide promotes weight loss after suboptimal response to bariatric surgery

Bemarituzumab extends survival in FGFR2b-overexpressing gastric cancer

Bemarituzumab extends survival in FGFR2b-overexpressing gastric cancer

First-line sacituzumab govitecan ups PFS in metastatic TBNC

First-line sacituzumab govitecan ups PFS in metastatic TBNC

Datopotamab deruxtecan improves survival in breast cancer patients not eligible for immunotherapy

Datopotamab deruxtecan improves survival in breast cancer patients not eligible for immunotherapy